Vesilute

Overview

"Vesilute" is a trade/market name used by a small number of research-peptide vendors. It is not a compound with any standing in primary scientific literature or regulatory databases. A search for the name returns zero results in PubMed, zero in PubMed Central, and no entry in cosmetic-ingredient or regulatory databases. In other words, essentially the entire public record of "Vesilute" consists of vendor marketing pages, several of which read as low-reliability, likely AI-generated SEO content and are internally inconsistent with one another.

Vendors self-describe "Vesilute" as a Khavinson-tradition "short peptide bioregulator" (the cytomedin/cytogen class) and claim its chemical identity is the dipeptide Glu-Asp (ED). That underlying dipeptide is chemically real and can be verified in PubChem (CID 99716, L-α-glutamyl-L-aspartic acid, C9H14N2O7, 262.22 g/mol, CAS 3918-84-1). Crucially, however, no primary source ties that molecule to the name "Vesilute," and "Vesilute" does not appear among that compound's PubChem synonyms. So even the most basic fact about this product — what it actually is — rests only on vendor assertion.

The marketing framing is also unstable. The actual vendor pages frame "Vesilute" around bladder / urinary tract / prostate "bioregulation" and cellular aging, while a separate common framing describes it as an under-eye "dark circles / microcirculation" cosmetic ingredient. Neither framing could be substantiated: no manufacturer, no INCI cosmetic-ingredient listing, and no clinical study for any product named "Vesilute" was found. This page therefore documents what is (and is not) known, and is candid that the honest answer is very little.

Chemistry and structure

There is no verified chemistry for "Vesilute" as a branded product. The table below reports the chemistry of the vendor-claimed identity (the Glu-Asp dipeptide) — which is a real, characterised compound — while making clear that the link between that molecule and the name "Vesilute" is not established.

The one solid fact here is narrow: the dipeptide vendors claim Vesilute to be (L-α-glutamyl-L-aspartic acid) genuinely exists and is catalogued. Everything connecting that fact to a product called "Vesilute" is vendor assertion, and at least one vendor page even reports a molecular formula (C9H14N2O6) that is inconsistent with the claimed dipeptide — a red flag for the reliability of the whole marketing corpus.

Mechanism of action

No mechanism has been demonstrated for any compound named "Vesilute." The claims below are vendor assertions with no cited studies, and are typical of generic Khavinson "cytogen" marketing language rather than findings tied to this specific name.

• Epigenetic / gene-expression modulation — vendors describe direct DNA interaction and gene-expression regulation, the standard Khavinson cytogen framing. [Hypothesis] (vendor marketing pages only; no cited study; no primary data located under this name).
• Smooth-muscle relaxation in bladder tissue / urinary tract and prostate support — asserted as the product's headline indication. [Hypothesis] (vendor marketing pages only; no animal or human study located under this name).
• Improved tissue microcirculation and reduced inflammation — including the under-eye "dark circles" framing. [Hypothesis] (vendor marketing pages only; the microcirculation/dark-circle framing could not be substantiated by any source).

Research and evidence

There is no research literature on a compound named "Vesilute." The "study" table below is mostly a record of absence of evidence, plus the one narrow chemistry fact about the claimed underlying molecule.

Human evidence. There are no human clinical trials for a compound named "Vesilute." A PubMed Central search returned zero results, and a general literature search found no peer-reviewed study using the name. [No human evidence located.] Every efficacy statement in circulation originates from vendor marketing pages, not from clinical or even preclinical data tied to this name.

Status and regulation

• FDA / EMA: No approval located from any regulator for a compound named "Vesilute."
• Cosmetic status: No INCI (cosmetic-ingredient) listing was found, despite a marketing "dark circles / microcirculation" framing; no manufacturer of such a cosmetic was located.
• How it is sold: Only by research-peptide vendors, labelled "for research use only." As with any such compound, it becomes an unauthorised/unlicensed medicine the moment it is intended for human use. This is a research-reagent classification, not permission for human use.
• WADA: No source addresses the sport-doping status of "Vesilute." It is not stated as prohibited by any source located — and "not stated as prohibited" is not affirmative permission. WADA sport-eligibility is a separate axis from legality; do not infer a class code where none is asserted.

Safety

• There is no safety data — no human, animal, or in-vitro safety evaluation — for any compound named "Vesilute." Absence of reported harm reflects absence of study, not a demonstration of safety.
• The identity and purity of material sold under this name are not established; vendor pages give inconsistent molecular formulas (e.g. C9H14N2O6 vs C9H14N2O7), which undermines confidence that buyers receive a defined, consistent substance.
• Because such material is sold as an injectable/reconstituted research peptide in unregulated channels, the usual risks of non-sterile, uncharacterised injectable products apply.

Legal status

Material sold as "Vesilute" is classified and handled as a research reagent ("for research use only") — a classification that carries no permission for human use. No regulator (FDA, EMA, or otherwise) has approved a compound under this name, and no cosmetic (INCI) listing exists. The absence of a specific ban is not affirmative permission: any such compound becomes an unauthorised, unlicensed medicine the moment it is intended for human use, and WADA sport-prohibition (where applicable) is a separate question from whether a substance is legal. Legal status varies by country and changes over time. This is not legal advice — verify the current rules in your own jurisdiction (dated 2026-07-08).

How it compares

• Epitalon is the archetypal Khavinson "short peptide bioregulator" — but unlike "Vesilute" it is at least a defined synthetic tetrapeptide (Ala-Glu-Asp-Gly) with a real, if weak and largely single-group, literature. "Vesilute" has no literature at all and an unverified identity.
• Thymalin is another Khavinson-tradition preparation whose evidence is limited, older, and mostly Russian. It illustrates the class's honest evidentiary ceiling — and even that thin base is far more than exists for "Vesilute," for which nothing peer-reviewed was found.

The recognised Khavinson vascular peptide is Vesugen (Lys-Glu-Asp, KED), not "Vesilute" — another reason to doubt that "Vesilute" is a genuine Khavinson-group name rather than a vendor coinage.

Common misconceptions

• "Vesilute is a known Khavinson peptide." No. The recognised Khavinson vascular peptide is Vesugen (KED). "Vesilute" is not an established name in Khavinson literature and appears to be a vendor coinage.
• "Vesilute is definitely the Glu-Asp dipeptide." That mapping is claimed only by vendors. No primary source confirms it, and "Vesilute" is not listed among the Glu-Asp dipeptide's PubChem synonyms.
• "There are studies showing it helps the bladder / prostate / dark circles." No study of any kind was found for a compound named "Vesilute." Every such claim is marketing, not data.
• "It has a CAS number, so it's a defined regulated product." The CAS 3918-84-1 belongs to the Glu-Asp dipeptide generally, not to the branded name "Vesilute." A CAS on the claimed molecule does not verify the branded product's identity, purity, or any effect.
• "No specific ban means it's fine to use." It does not. Absence of a ban is not permission; any compound intended for human use becomes an unauthorised medicine, and a research-reagent label is not a green light.

Russian research

Much of what circulates about "Vesilute" borrows its authority from Russian peptide-bioregulator research — chiefly the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson's school) and its collaborators — but for this specific compound that literature is thin, off-target, and included here only for completeness and honest framing. Critically, no primary study exists under the names "Vesilut" or "Vesilute," and there is no primary study of the isolated Glu-Asp (ED) dipeptide on bladder or urinary tissue at all (verified by direct PubMed searches). A widely repeated vendor/SEO claim that "Vesilute normalized detrusor contractility in rat models of infravesical (bladder-outlet) obstruction" could not be tied to any PMID, DOI, or CyberLeninka URL — a search for "Khavinson detrusor" returns zero PubMed results — and should be treated as unsupported and likely fabricated. Vendors do not even agree on what the molecule is: some sell "Vesilut/Vesilute" as the Glu-Asp (ED) dipeptide, others as a Lys-Glu-Asp (KED) tripeptide — a basic identity disagreement that no primary source resolves.

The genuinely verifiable Russian bladder-relevant work is about different peptides, not the Glu-Asp compound vendors call Vesilut:

• [Animal] In male rats with chemically induced urinary-bladder carcinogenesis, the dipeptide Vilon (Lys-Glu, KE) — not Glu-Asp — reduced tumor incidence to 56% versus 75.5% in controls and roughly halved preneoplastic/early-neoplastic mucosal changes. Pliss GB, Mel'nikov AS, Malinin VV, Khavinson VK. Bull Exp Biol Med 2001;131(6):558-560. PMID 11586406; DOI 10.1023/a:1012354603132. This is the closest real bladder-tissue Khavinson study, but it tests Vilon, not the Glu-Asp compound.
• [Animal] In a parallel report on induced bladder neoplasms, Vilon (Lys-Glu) again lowered tumor incidence (56% vs 75.5% control) while Epitalon (Ala-Glu-Asp-Gly) showed no inhibitory effect. Pliss GB, Mel'nikov AS, Malinin VV, Khavinson VKh. Vopr Onkol 2001. PMID 11785104. Notably, even the tetrapeptide that contains a Glu-Asp motif did nothing here — which, if anything, undercuts the idea that a Glu-Asp-containing peptide is inherently bladder-protective.
• [In vitro] / [Animal] Prostatilene — a crude prostate-tissue cytomedin extract, not a defined dipeptide — increased the contractile activity of isolated bladder smooth-muscle cells from male Wistar rats. Barabanova VV, Gorbachev AG, Parastaeva MM, Khavinson VKh. Fiziol Zh Im I M Sechenova 1993. PMID 8330080. The direction of effect (enhanced, not relaxed contractility) contradicts the vendor "detrusor relaxation" narrative.

Two further papers are frequently mis-cited by vendors to lend a bladder-specific claim borrowed authority, but neither mentions bladder or the Glu-Asp dipeptide:

• [Hypothesis] A computational (in silico) study proposing that Lys-Glu (KE) and Ala-Glu-Asp-Gly (AEDG/Epitalon) could bind cytokine-gene promoter regions and modulate expression. Kuznik BI, Tarnovskaya SI, Lin'kova NS, Khavinson VKh. Vestnik Gematologii 2013 (open-access full text on CyberLeninka: https://cyberleninka.ru/article/n/vliyanie-dipeptida-lys-glu-i-tetrapeptida-ala-glu-asp-gly-na-ekspressiyu-genov-provospalitelnyh-protivovospalitelnyh-i-immunnyh (opens in a new tab)). It contains no reference to bladder and is a molecular-modelling hypothesis, not a wet-lab result.
• [In vitro] A generic demonstration that short (2-4 aa) peptides can inhibit or stimulate DNA hydrolysis by eukaryotic endonucleases depending on methylation/histone context. Khavinson VKh, Fedoreyeva LI, Vanyushin BF. Bull Exp Biol Med 2011. PMID 22442805. This is the class-level "peptides interact with DNA" paper cited as if it proved a Vesilut-specific bladder mechanism; it does not mention Vesilut, Glu-Asp, or bladder.

Several vendor claims have no locatable source and are flagged rather than cited: that "Vesilut/Vesilute" is the Glu-Asp dipeptide (vendors also market it as the Lys-Glu-Asp tripeptide, and no primary source settles which); that it is a formally synthesized "Cytogen" with its own patent/development history; the mechanistic assertions of "inhibition of glycogen aggregation in bladder smooth muscle," "attenuated calcium signaling," and "detrusor relaxation"; and marketed efficacy for chronic cystitis, prostatitis, or BPH. Russian-language sources describe these ideas, but no independently verifiable citation was found for any of them.

On regulatory status: keep it distinct from efficacy. The product vendors sell as "Vesilut"/"Vesilute" is marketed as the synthetic "Cytogen"-class counterpart of the natural bladder cytomedin Chitomur (Читомур), extracted from animal bladder tissue by Khavinson's institute and its commercial arms (NPCRIZ / "Peptides" / gerontology.ru). In Russia these bladder products are sold as BAD — biologically active additives (dietary supplements), freely purchasable in pharmacies and vendor sites, and are not registered pharmaceutical medicines with an approved bladder indication; the "normalizes bladder function" language is supplement marketing. Outside Russia there is no FDA/EMA approval, and the compound is handled as a research-use-only reagent.

On quality: the evidence for "Vesilute" specifically is effectively non-existent, and the adjacent Khavinson bladder literature is small, single-group, near-exclusively from one St. Petersburg institute and its collaborators, older (1993-2013), animal/in-vitro or purely computational, and not independently replicated outside Russia. Being sold or used as a bladder supplement in Russia is a regulatory and marketing fact, not proof of efficacy — and it should not be read as upgrading the evidence level for this compound.